ASTRAZEN share price, P/E, ROE & financials

AstraZeneca Pharma India (ASTRAZEN) had a P/E of 89.7× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 33% below their 52-week high. Its ROCE of 25% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 31% and 24% a year over 3 years. Its dividend yield is 0.6%, and debt is 0.13× equity. It is a small-cap company with a market cap of ₹15,934 Cr, ranked 28th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 34% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹6,294.00
Day high: ₹6,801.00
Day low: ₹6,294.00
Prev. close: ₹6,294.00
Volume: 62.2K

Health check

2 good · 1 fair · 3 to check

ReturnsBehind
−34.5% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 89.7 vs industry 28.7.
GrowthStrong
Sales +31.3%, profit +23.6% a year over 3 years.
ProfitabilityStrong
ROCE 25.5% vs peer median 17.9%.
Balance sheetFair
Debt 0.13× equity, interest covered 57.2×, Piotroski 4 of 9.
Red flags2 to check
P/E of 89.7 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹15,934 Cr, #28 of 154 in its industry by size.

Defensive

Beta 0.22 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹2,432 Cr · profit ₹170 Cr

Market cap: ₹15,934 Cr; Small cap
P/E: 89.7; Industry 28.7
Price to book: 18.26; Peers 4.99
Dividend yield: 0.57%
ROE: 22.8%; Peers 14.7%
ROCE: 25.5%; Peers 17.9%
Debt to equity: 0.13; Debt ₹111 Cr
EPS (TTM): ₹71.09; Face value ₹2
OPM (TTM): 9.6%; Net margin 7.0%
Sales growth: +30.4%; Latest quarter vs a year ago
Profit growth: +15.0%; Latest quarter vs a year ago
Price to sales: 6.55; EV/EBITDA 69.1

Strengths

Return on equity of 22.8%.
Return on capital employed of 25.5%.
Quarterly sales up 30.4% on a year ago.

Risks to check

P/E of 89.7 against an industry P/E of 28.7.
33% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes. The company serves distributors, hospitals, and…

Headquarters: Bengaluru
Employees: 600
Sector: Healthcare
ISIN: INE203A01020
Website: astrazeneca.in

Price range

52 weeks

₹5,640.00₹9,469.50

Today

₹6,294.00₹6,801.00

Avg volume (3M): 11.7K
1-year return: minus 34.5%
From 52-week high: minus 32.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
ASTRAZENAstraZeneca Pharma India	6,373.50	plus 1.26%	15,934	89.7	18.26	25.5%	22.8%	9.5%	31.3%	23.6%	0.57%	minus 34.5%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
559	612	579	683	729
484	567	518	634	634
75.2	44.8	60.9	48.9	95.6
13.4%	7.3%	10.5%	7.2%	13.1%
6.2	5.1	6	9.2	15.1
0.7	1.1	2	2	1.9
2.6	3.8	5.6	5.2	5.4
−5.3	1.5	−1.1	−0.2	−15
72.8	46.5	58.1	50.8	88.5
25.5%	30.0%	22.8%	25.3%	29.6%
54.2	32.6	44.9	37.9	62.3
21.69	13.04	17.95	15.17	24.93

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +31.3%
Profit CAGR 3Y: +23.6%
EPS CAGR 3Y: +23.6%
ROE: 22.8%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,003	1,296	1,713	2,273
–	+29.2%	+32.2%	+32.6%
838	1,109	1,515	2,009
165	186	198	263
16.5%	14.4%	11.5%	11.6%
23.6	34.1	88.3	24.8
0.6	1.2	1.5	4.5
16.3	14.9	40	28.6
−37.8	15.2	−88.3	−2.8
134	220	156	252
26.0%	26.4%	26.0%	25.6%
99.3	162	116	188
–	+62.7%	minus 28.3%	+62.0%
39.70	64.60	46.30	75.00

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
5	5	5	5
584	707	765	868
7.2	4.6	35.7	111
389	362	712	1,006
985	1,078	1,518	1,989
70.2	64.8	63.6	117
1.7	0.7	–	–
3.1	–	3.7	4
500	506	536	448
410	507	915	1,420
985	1,078	1,518	1,989

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
58.3	27.9	65.4	−15.1
18.1	21.7	30.8	18.7
−24.5	−44.4	−65.6	−92
51.9	5.2	30.6	−88.4
−8.5	−10.8	−1.8	−3.6
49.8	17.1	63.6	−18.8
−20	−40	−60	−80

Shareholding pattern

Source: NSE filings

75.0%

promoters

Promoters75.00%
Public25.00%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	75.00%	25.00%	0.00
30 Jun 2026	75.00%	25.00%	0.00
31 Mar 2026	75.00%	25.00%	0.00
31 Dec 2025	75.00%	25.00%	0.00
30 Sep 2025	75.00%	25.00%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you